In this study, by bioinformatic analysis, experiments in vitro and clinical RCC samples, we report herein that PUS1 expression was closely associated with RCC progression and the upregulated PUS1 expression results in the elevated RCC cancer cell viability and mobility, providing with the evidence that PUS might be a promising treatment target for RCC therapy. Here, PUS1 is linked to cancer.